Intra-abdominal Infections

Appendicitis & Infections of the Liver and Biliary System

Russell E. Lewis

2026-03-01

Intraabdominal Infections, Part 2



Prof. Russell E. Lewis
Department of Molecular Medicine
University of Padua


russelledward.lewis@unipd.it
https://github.com/Russlewisbo


slides available at: www.padovaid.com

What is appendicitis?



  • Acute inflammation of the vermiform appendix
  • Often related to obstruction
  • Complicated by polymicrobial infection
  • Complications: perforation, peritonitis, intra-abdominal abscesses

Epidemiology: By the Numbers



  • Lifetime risk: 8.6% in men, 6.7% in women
  • ~108 cases per 100,000 person-years (US)
  • 190,000 appendectomies in the US (2018)
  • 42% decrease in appendectomies since 2011
  • Mortality <1% (but ≥5% in elderly)

Age and Sex Distribution



  • Peak incidence: 15–25 years
  • Rare in infants
  • Declines after age 45 (<25% of cases)
  • Male-to-female ratio: 1.4:1
  • Most common surgery for individuals ≤17 years

Geographic Variation


  • Lower incidence in rural, nonindustrialized areas
  • Incidence increases with industrialization
  • Similar pattern seen with diverticulitis
  • Estimated lifetime risk <1% in rural sub-Saharan Africa

Anatomy of the appendix

  • Tube-shaped structure, 5–10 cm long
  • Arises 2–3 cm below terminal ileum
  • Medial posterior wall of cecum
  • Common atypical positions: descending pelvic, transverse retrocecal, ascending postileal


The Appendix: Not just vestigial


  • Contributes to gut microbiome homeostasis
  • Mucus-rich biofilm houses resident bacteria
  • Acts as a microbial “sanctuary”
  • Repopulates gut after diarrheal illness
  • Sheds bacteria at 2–3 mL/day

Classic pathogenesis model


  1. Luminal obstruction (fecaliths, foreign bodies, tumor)
  2. Mucus accumulation → increased intraluminal pressure
  3. Lymphatic/vascular compression
  4. Ischemic mucosal damage
  5. Microbial invasion and inflammation
  6. Gangrene → perforation (if untreated)

Challenging the classic pathology model


  • Fecaliths found in only a minority of cases
  • Medical (antibiotic) treatment alone is effective in many patients
  • Alternative etiologies proposed:
    • Infectious agents
    • Dietary fiber deficiency
    • Microbiome dysbiosis
    • Genetic susceptibility
    • Environmental factors

The dietary fiber hypothesis


  • Short’s observation (early 20th century): UK vs. Africa comparison
  • Burkitt’s hypothesis: fiber as bulking agent reduces risk
  • Fiber prevents fecalith formation and impaction
  • Microbiome influenced by dietary fiber content
  • Interest in diet–microbiome–appendicitis axis growing

Microbiology: Culture-based


  • 10–14 organisms typically can be cultured from inflamed appendix

  • Reflects colonic microbiota

  • Key organisms:

    • Escherichia coli

    • Bacteroides fragilis group

    • Prevotella spp.

    • Peptostreptococcus spp.

    • Streptococcus anginosus group

Microbiology: 16S rRNA Insights


  • Appendiceal microbiome is remarkably diverse

  • Dozens of phyla, hundreds of species

  • Distinct from other GI tract locations

  • Enriched in inflamed appendix:

    • Fusobacterium

    • Peptostreptococcus

    • Parvimonas

  • Dysbiosis may drive appendicitis (not obstruction)

Specific pathogens to know


Organism Presentation
Yersinia spp. Ileocecitis, mesenteric adenitis → mimics appendicitis
Campylobacter Pseudoappendicitis with ileocecitis
Salmonella Pseudoappendicitis with mesenteric adenitis
E. histolytica True appendicitis (rare)
Viruses (EBV, CMV, measles) Mesenteric adenitis

Classic clinical presentation


  1. Early: Colicky, visceral periumbilical pain
  2. 6–24 hours: Migration to RLQ (somatic pain)
  3. Pain at McBurney point (anterior appendix)
  4. Associated: low-grade fever, anorexia, nausea, vomiting

Physical examination signs


Sign Description
Rovsing sign RLQ pain with LLQ palpation
Psoas sign Pain with active hip extension
Obturator sign Pain with internal hip rotation
Guarding Involuntary muscle contraction
Rebound tenderness Pain on release of pressure

Diagnostic Challenges


Warning

Diagnosis is more difficult in:

  • Women of childbearing age (gynecologic mimics)

  • Pelvic appendixes (pelvic/LLQ pain)

  • Third-trimester pregnancy (RUQ pain shift)

  • Elderly patients (atypical presentations)

  • Young children (inability to localize pain)

CT Imaging: Normal vs. abnormal


Imaging


  • CT with IV contrast: Sensitivity and specificity both >95%
    • Preferred in adults
    • Dilated appendix >6 mm, periappendiceal fat stranding
  • Ultrasonography: First-line in children and pregnant women
    • Sensitivity 70–90%
  • MRI: Alternative in pregnancy

Scoring systems

Alvarado Score (MANTRELS): migration, anorexia, nausea, tenderness, rebound, elevated temp, leukocytosis, shift to left


Letter Clinical Feature Points
M Migration of pain to right lower quadrant 1
A Anorexia 1
N Nausea/vomiting 1
T Tenderness in right lower quadrant 2
R Rebound pain 1
E Elevated temperature (>37.3°C) 1
L Leukocytosis (>10,000/mm³) 2
S Shift to left (neutrophilia >75%) 1

Alvarado Score (MANTRELS): Interpretation

Score Risk Recommendation
1–4 Low Appendicitis unlikely; consider discharge with observation
5–6 Equivocal/intermediate Further workup warranted (imaging, observation, surgical consult)
7–8 High Likely appendicitis; surgical consultation indicated
9–10 Very high Appendicitis highly probable; proceed to surgery

IR Score (Appendicitis Inflammatory Response):

Total: 0–12 points
Variable Criteria Points
Vomiting Present 1
Right lower quadrant pain Present 1
Rebound tenderness or muscular defense Mild 1
Moderate 2
Strong 3
Temperature ≥ 38.5°C 1
Leukocytosis (×10⁹/L) 10.0–14.9 1
≥ 15.0 2
Proportion of neutrophils (%) 70–84% 1
≥ 85% 2
CRP (mg/L) 10–49 1
≥ 50 2

IR score interpretation

Interpretation

Score Risk Recommendation
0–4 Low Appendicitis unlikely; discharge with observation
5–8 Indeterminate Imaging, active observation, or surgical consult
9–12 High Appendicitis highly probable; surgical intervention

Key advantages over Alvarado

  • CRP is included — a more sensitive and specific acute-phase reactant than WBC alone

  • Graded variables — rebound tenderness, PMN%, WBC, and CRP are each weighted by severity rather than binary yes/no

  • Higher specificity for ruling in appendicitis, and better negative predictive value for low scores

  • Performs well in both sexes, with some studies showing superior performance to Alvarado in women

  • Validated in multiple prospective European and international cohorts

Treatment: Surgical

  • Laparoscopic appendectomy:
    Standard of care
    • Shorter hospital stay
    • Less postoperative pain
    • Lower wound infection rates
  • Open appendectomy: reserved for complex cases
  • Interval appendectomy: considered after initial conservative management of appendiceal abscess

Treatment: Antibiotic-first strategy


Tip

An “antibiotic first” strategy has emerged as a safe and effective option for uncomplicated appendicitis

  • Avoids surgery in ~60–70% of patients
  • Outcomes comparable to appendectomy
  • Recurrence rate ~25–30% at 5 years
  • Patient selection is key: uncomplicated, no fecalith

Antibiotic regimens for appendicitis


  • Uncomplicated: Piperacillin-tazobactam or ceftriaxone + metronidazole
  • Perforated: IV antibiotics 3–5 days → oral step-down
  • Duration guided by clinical response
  • Ensure anaerobic coverage (metronidazole)

Appendicitis: Key takeaways



  • Most common surgical emergency of the abdomen
  • Classic: periumbilical pain → RLQ migration
  • CT is the imaging gold standard in adults
  • Laparoscopic appendectomy remains definitive treatment
  • Antibiotic-first strategy: valid for uncomplicated cases
  • Microbiome dysbiosis: emerging pathogenic concept

Infections of the liver
and biliary system

Liver abscess: Two categories


Feature Amebic Pyogenic
Cause E. histolytica Bacterial
(polymicrobial or monomicrobial)
Pathology Hepatocyte apoptosis Suppurative infection
“Pus” appearance Anchovy paste (nonpurulent) Purulent
Primary treatment Medical (metronidazole) Drainage + antibiotics

Amebic Liver Abscess: Epidemiology


  • Rare in the US (travelers, immigrants, MSM)
  • 2,983 total cases of amebiasis in 1994
  • Annual incidence decreasing 2.4% per year
  • Worldwide: E. histolytica second only to malaria as cause of death from parasitic disease
  • Male: female ratio = ranging from 5–18 : 1 in epidemiological studies

E. histolytica vs. E. dispar


  • E. dispar: nonpathogenic, colonizes 5–25% of persons
  • E. dispar has no propensity for invasive disease
  • Cannot distinguish by microscopy
  • In industrialized countries: most Entamoeba = E. dispar
  • In endemic regions: E. histolytica may predominate

Pyogenic liver abscess: epidemiology


  • Incidence: 1–4 per 100,000 annually (US/Europe)
  • In Asia: 5–10× higher (community-acquired K. pneumoniae)
  • Peak: 5th–6th decades of life
  • 50% solitary; right lobe most common
  • Biliary disease: now the leading cause

Routes of hepatic invasion


Route Frequency
Biliary tree (cholangitis) 40–50%
Cryptogenic 20–40%
Portal vein (pylephlebitis) 5–15%
Hepatic artery (bacteremia) 5–10%
Direct extension 5–10%
Trauma 0–5%

Risk factors for pyogenic liver abscess


  • Diabetes mellitus: >3× risk
  • Biliary disease (gallstones, obstruction)
  • Hepatobiliary procedures
  • Chronic granulomatous disease
  • Hemochromatosis (especially Yersinia)
  • Malignancy
  • Cirrhosis
  • Immunosuppression

Pathogenesis: Amebic liver abscess


  1. Ingestion of E. histolytica cysts
  2. Excystation in intestinal lumen
  3. Trophozoites migrate to colon
  4. Adhere via Gal/GalNAc lectin
  5. ~10% develop symptomatic colitis
  6. Portal spread to liver in <1% of cases
  7. Apoptosis of hepatocytes → abscess formation

“Anchovy paste” from liver abscess

Virulence Factors of E. histolytica


Factor Function
Gal/GalNAc lectin Epithelial adherence
Amoebapores Pore formation in target cell membranes
Cysteine proteases Tissue invasion, immune evasion
Apoptosis induction Hepatocyte and neutrophil killing

Host Factors in Amebic Liver Abscess


  • HLA-DR3: increased susceptibility
  • Testosterone: risk factor (10× higher in men)
  • Host defense mechanisms:
    • Complement
    • Neutrophils
    • Interferon-γ
    • Nitric oxide
    • Adaptive immunity

Microbiology of Pyogenic Liver Abscess


  • Cultures positive in 80–90% of cases

  • Polymicrobial in 20–50% , key organisms:

    • E. coli and K. pneumoniae (most common gram-negatives)

    • Streptococcus anginosus group (most common gram-positive) -

    • Bacteroides spp. (most common anaerobe)

    • Anaerobes recovered in 15–30%

Epidemic K. pneumoniae liver abscess


  • First noted in Taiwan in mid-1980s

  • Monomicrobial, often in diabetics

  • No biliary tract disease

  • Now accounts for 80% of cases in Asia

    • Spreading globally - Capsular serotypes K1 and K2

Mucoid phenotype demonstrated by loop test

K. pneumoniae virulence determinants


  • Capsular polysaccharide (K1/K2 serotypes)
  • magA gene → hypermucoviscosity
  • cps gene cluster (25-kb chromosomal element)
  • RmpA (mucoid phenotype regulator)
  • Aerobactin (iron acquisition)
  • Virulence plasmids (pLVPK, pK2044)

Convergent drug-resistant K. pneumoniae


Warning

Public Health Threat

  • Classic hypervirulent strains: typically drug sensitive
  • MDR/XDR strains can acquire virulence plasmids
  • Or hypervirulent strains can acquire resistance plasmids
  • Fatal ventilator-associated pneumonia outbreaks in China
  • Only a minority currently show hypervirulent phenotypes in lab

Clinical features: Amoebic liver abscess


  • Fever + dull, aching RUQ pain

  • Only 15–35% have GI symptoms

  • Acute (<2 weeks) in ~2/3 of cases

  • Can develop months to years after travel

  • Risk factors: male sex, corticosteroid use

  • Indistinguishable from pyogenic on clinical grounds alone

Clinical Features: Pyogenic Liver Abscess


  • Classic triad (fever, jaundice, RUQ tenderness) in only 10%
  • Most common: fever without localizing signs
  • General failure to thrive
  • Malaise, fatigue, anorexia, weight loss
  • Hematogenous abscesses present most acutely (3 days)
  • Pylephlebitis-related abscesses: longest duration (42 days)

Comparing amoebic vs. Pyogenic liver abscess


Feature Amebic Pyogenic
Male:female 5–18:1 1–2.4:1
Age 30–40 50–60
Duration (days) <14 5–26
Mortality 10–25% 0–5%
Abdominal pain 80% 55%
RUQ tenderness 75% 25–55%

Diagnosis: Laboratory findings


  • Leukocytosis: present in most patients (75–80%)
  • Elevated alkaline phosphatase: most common abnormal LFT (~2/3)
    • Normal value does not exclude diagnosis
  • Transaminases: generally mildly elevated
  • Procalcitonin: typically elevated
  • Albumin and PT: usually normal

Diagnosis: imaging


Modality Sensitivity Best For
Ultrasonography 70–90% Initial assessment,
biliary disease
CT (contrast-enhanced) ~95% Definitive diagnosis,
drainage guidance
MRI High Distinguishing from neoplasia
Fine-needle aspiration Definitive Diagnostic confirmation

Diagnosis: amoebic serology


  • Enzyme immunoassay: sensitivity 65–92%, highly specific

  • Can be negative if symptom duration <2 weeks

  • Repeat serology in 1–2 weeks usually positive

  • Positive serology confirms present or prior infection

  • Cannot distinguish from extraintestinal disease

  • ELISA for Gal/GalNAc lectin: >95% sensitivity in serum

Emerging diagnostics


  • Molecular multiplex panels:
    • Highly sensitive for amebic colitis

    • Patients with liver abscess usually don’t have concurrent intestinal infection

    • PCR: Potential for aspirated fluid; limited to research labs

    • cfDNA testing: Circulating cell-free DNA

      • Recent study: 90% sensitivity, 100% specificity for amoebic abscess

      • Noninvasive blood-based assay

Treatment: Amoebic liver abscess — Medical therapy


Tip

Almost always treatable with medical therapy alone

Drug Regimen
Metronidazole 750 mg TID × 7–10 days
Tinidazole 2 g daily × 3 days
Secnidazole/Ornidazole Extended half-life alternatives
Paromomycin (luminal agent) Follow-up to eliminate colonization

Treatment: When to drain amoebic abscess


  • Uncomplicated: drainage NOT required

  • Indications for drainage: - No response to medical therapy (>5–7 days)

  • Diagnostic uncertainty (rule out pyogenic)

  • Large lesions at risk for rupture:

    • Left-sided abscesses (pericardial rupture risk)

    • Bacterial superinfection (1–5% of cases)

    • Percutaneous preferred over surgical drainage

Treatment: Pyogenic Liver Abscess — Drainage


  • Percutaneous catheter drainage: Preferred primary therapy

    • Success rate: 69–90%

    • Can be performed at time of diagnosis

    • Catheter left in place 5–14 days until drainage resolves

    • Recent success rates with antibiotics: 80–95% (even for >10 cm abscesses)

    • Surgical drainage if: percutaneous fails, concurrent surgical disease, multiple/loculated abscesses

Treatment: Pyogenic liver abscess — Antibiotics


Approach Agents
Monotherapy Piperacillin-tazobactam OR carbapenem
Combination 3rd/4th-gen cephalosporin + metronidazole OR fluoroquinolone + metronidazole

Antibiotic Duration: An open question


  • No RCTs establishing optimal duration

  • Meta-analysis: pooled mean 32.7 days

    • oTraditional: IV 2–3 weeks → oral 4–6 weeks total

    • Some evidence for shorter courses (2–4 weeks)

  • Singapore RCT: 4-week oral ciprofloxacin noninferior to 4-week IV ceftriaxone for K. pneumoniae

  • Follow-up imaging to guide duration

Aspiration vs. catheter drainage


Feature Aspiration Catheter Drainage
Success rate 58–88% (≤5 cm) 69–90%
Recurrence Higher Lower
Meta-analysis evidence Drainage superior Drainage superior
Best for Small, solitary abscesses Larger, multiple abscesses

Biliary tract infections

Biliary system infections: Overview

  • Infections associated with
    obstruction to bile flow

  • Gallstones: common and usually asymptomatic

  • 1% to 4% complicated by acute cholecystitis

    • Over 100,000 cholecystectomies per year in Italy

    • 2–15% of cases are acalculous cholecystitis


Cholecystitis: Key points

  • Inflammation/bacterial infection of the gallbladder
  • Usually from obstructing gallstones
  • Acalculous cholecystitis: similar process without stones
  • Treatment: cholecystectomy + antibiotics
  • Mortality higher in acalculous cases


Cholangitis: Key points

  • Inflammation/infection of the bile ducts
  • Charcot triad: fever, jaundice, RUQ pain
  • Reynolds pentad: triad + hypotension + altered mental status (sepsis)
  • Life-threatening emergency requiring urgent biliary decompression
    not an encapsulated infection and will spill over to abdomen and bloodstream
  • Mortality: 5–10% with treatment; up to 90% without

ERCP or percutaneous transhepatic drainage

Antibiotic therapy billary tract infections

Good Penetration (ABSCR ≥1) ABSCR Low Penetration (ABSCR <1) ABSCR
Piperacillin/tazobactam 4.8 Ceftriaxone 0.75
Tigecycline >10 Cefotaxime 0.23
Amoxicillin/clavulanate 1.1 Meropenem 0.38
Ciprofloxacin >5 Ceftazidime 0.18
Ampicillin/sulbactam 2.4 Vancomycin 0.41
Cefepime 2.04 Amikacin 0.54
Levofloxacin 1.6 Gentamicin 0.30
Penicillin G >5
Imipenem 1.01



ABSCR = Antibiotic Bile/Serum Concentration Ratio. Source: Ansaloni et al. PMID 27307785

Biliary tract infections: Mild–moderate severity

  • Community-acquired

  • No prior biliary instrumentation

  • Low resistance risk

Regimen Agents
3rd-gen cephalosporin Ceftriaxone, cefotaxime
2nd-gen cephalosporin Cefuroxime
1st-gen cephalosporin Cefazolin (cholecystitis only)
Fluoroquinolone Ciprofloxacin, levofloxacin (if local resistance permits)
β-lactam/β-lactamase inhibitor Amoxicillin/clavulanate
<<<<<<< HEAD

Note

Anaerobic coverage not required unless bilioenteric anastomosis or prior biliary intervention

Biliary Tract Infections: Severe / Healthcare-Associated

=======


::: callout-note Anaerobic coverage not required unless bilioenteric anastomosis or prior biliary intervention :::

Biliary tract infections: Severe / healthcare-associated

>>>>>>> ee3445f (Add Alvarado/IR score interpretation slides, fix typos, add citations, update styling)
  • Grade III cholangitis

  • Prior instrumentation

  • Healthcare-acquired

  • High resistance risk

Regimen Agents
Carbapenem Imipenem/cilastatin, meropenem, ertapenem
β-lactam/β-lactamase inhibitor Piperacillin/tazobactam
Fluoroquinolone + anaerobic cover Ciprofloxacin or levofloxacin + metronidazole


Additional considerations:

  • Add vancomycin if MRSA risk (prior MRSA, healthcare-associated)
  • Add fluconazole if Candida risk (immunosuppressed, prolonged prior antibiotics)
  • Adjust for local antibiogram — fluoroquinolone resistance in E. coli >10% in many centers

Summary: Comparing hepato-biliary infections



Appendicitis Amebic Abscess Pyogenic Abscess
Peak age 15–25 30–40 50–60
Cause Obstruction/dysbiosis E. histolytica Biliary/polymicrobial
Diagnosis CT Serology + imaging Culture + imaging
Treatment Surgery or antibiotics Metronidazole Drainage + antibiotics

Clinical decision algorithm: Liver abscess

  1. Suspect: Fever + RUQ pain/tenderness + leukocytosis
  2. Image: CT with contrast (or US if CT not available)
  3. Differentiate: Serology, epidemiology, aspirate if needed
  4. Treat:
    • Amebic → Metronidazole + paromomycin
    • Pyogenic → Drainage + empiric antibiotics
  5. Follow up: Imaging to confirm resolution

Take-Home Messages

  1. Appendicitis: Most common surgical emergency; antibiotic-first is valid for uncomplicated cases
  2. Amebic liver abscess: Think travel/endemic exposure; treat medically with metronidazole
  3. Pyogenic liver abscess: Drainage + antibiotics; think K. pneumoniae in diabetics
  4. Klebsiella pneumoniae: Global emergence of hypervirulent strains; convergent MDR strains are a growing threat
  5. Microbiome: Paradigm shift in understanding appendicitis pathogenesis

References

1.
Dimitrios Moris, Erik Karl Paulson, Theodore N. Pappas. Diagnosis and management of acute appendicitis in adults: A review. JAMA. 2021 Dec;326(22):2299–311. doi:10.1001/jama.2021.20502
<<<<<<< HEAD
2.
John C. Lam, William Stokes. Management of pyogenic liver abscesses: Contemporary strategies and challenges. Journal of Clinical Gastroenterology. 2023 Sep;57(8):774. doi:10.1097/MCG.0000000000001871
=======
2.
A randomized trial comparing antibiotics with appendectomy for appendicitis. New England Journal of Medicine. 2020 Nov 11;383(20):1907–19. doi:10.1056/NEJMoa2014320
3.
Paulina Salminen, Hannu Paajanen, Tero Rautio, Pia Nordström, Markku Aarnio, Tuomo Rantanen, Risto Tuominen, Saija Hurme, Johanna Virtanen, Jukka-Pekka Mecklin, Juhani Sand, Airi Jartti, Irina Rinta-Kiikka, Juha M. Grönroos. Antibiotic therapy vs appendectomy for treatment of uncomplicated acute appendicitis: The APPAC randomized clinical trial. JAMA. 2015 Jun 16;313(23):2340–8. doi:10.1001/jama.2015.6154
4.
John C. Lam, William Stokes. Management of pyogenic liver abscesses: Contemporary strategies and challenges. Journal of Clinical Gastroenterology. 2023 Sep;57(8):774. doi:10.1097/MCG.0000000000001871
5.
Joseph S. Solomkin, John E. Mazuski, John S. Bradley, Keith A Rodvold, Ellie J. C. Goldstein, Ellen J. Baron, Patrick J. O’Neill, Anthony W. Chow, E. Patchen Dellinger, Soumitra R. Eachempati, Sherwood Gorbach, Mary Hilfiker, Addison K. May, Avery B. Nathens, Robert G. Sawyer, John G. Bartlett. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the surgical infection society and the infectious diseases society of america. Clinical Infectious Diseases. 2010 Jan 15;50(2):133–64. doi:10.1086/649554
>>>>>>> ee3445f (Add Alvarado/IR score interpretation slides, fix typos, add citations, update styling)